Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase

References

• Gale R P, Hehlmann R, Zhang M J, Hasford J, Goldman J M, Heimpel H, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukaemia The German CML Study Group. Blood 1998; 91(5)1810–1819
   PubMed Web of Science ®Google Scholar
• McGlave P B, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–1488
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szydlo R M, Hermans J, Devergie A, Frassoni F, Arcese W, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20(7)553–560
   PubMed Web of Science ®Google Scholar
• Goldman J M. Optimizing treatment for chronic myeloid leukemia. N Eng J Med 1997; 337: 270–271
   PubMed Web of Science ®Google Scholar
• Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998; 92(5)1541–1548
   PubMedGoogle Scholar
• Allan N C, Richards S M, Shepherd P CA. UK Medical Research Council randomised, multicentre trial of interferon - α for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003; 17(8)1529–1537
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelererated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• To L B, Haylock D N, Dowse T, Simmons P J, Trimboli S, Ashman L K, et al. Comparative study of the phenotype and proliferative capacity of peripheral CD 34+ cells mobilized by four different protocols and those of steady – state PB and bone marrow CD 34+ cells. Blood 1994; 84(2930)
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Juneau A L, Carlson R O, Zinsmeister A R, Jalal S M, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar
• Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen A C, Landegren U. Minifold-assisted reverse transcription-PCR with real time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 2000; 46: 913–920
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Deisseroth A B, Zu Z, Claxton D, Hanania E G, Fu S, Ellerson D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukaemia contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Verfaillie C M, Bhatia R, Miller W, Mortari F, Roy V, Burger S, et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87(11)4770–4779
   PubMed Web of Science ®Google Scholar
• Petzer A L, Eaves C J, Lansdorp P M, Ponchio L, Barnett M J, Eaves A C. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996; 88: 2162–2171
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, et al. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 1999; 93(11)3973–3982
   PubMed Web of Science ®Google Scholar
• De Fabritiis P, Petti M C, Montefusco E, De Propris M S, Sala R, Bellucci R, et al. BCR-ABL antisense. Oligodoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156–3162
   PubMed Web of Science ®Google Scholar
• Heinzinger M, Waller C F, Rosenstiel A, Scheid S, Burger K J, Lange W. Quality of IL-3 and G-CSF mobilised peripheral blood stem cells in patients with early chronic phase CML. Leukemia 1998; 12: 333–339
   PubMed Web of Science ®Google Scholar
• Becker M, Fabrega S, Belloc F, Rice A, Barbu V, Reiffers J. Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 1993; 12: 155–158
   PubMed Web of Science ®Google Scholar
• Gewirtz A. Treatment of CML with c-myc antisense oligodeoxynucleotides. Bone Marrow Transplant 1994; 14(Suppl 3)S57–S61
   PubMed Web of Science ®Google Scholar
• Luna-Bautista F, Sanchez-Valle E, Ayala-Sanchez M, Morales-Polanco M, Meillon-Garcia L, Benitez-Bribiesca L, et al. Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in dexter-type long-term cultures. Hematology 2003; 8(3)155–163
   PubMedGoogle Scholar
• Kiehntopf M, Esquivel E L, Brach M A, Herrmann F. Clinical applications of ribozymes. Lancet 1995; 345: 1027
   PubMed Web of Science ®Google Scholar
• Pachuk C J, Yoon K, Moelling K, Coney L R. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 1994; 22: 301
   PubMed Web of Science ®Google Scholar
• Carella A M, Podesta M, Frassoni F, Raffo M R, Pollicardo N, Pungolino E, et al. Collection of “normal” blood repopulating cells during early hematopoetic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267–271
   PubMed Web of Science ®Google Scholar
• Carella A M, Lerma E, Corsetti M T, Dejana A, Basta P, Vassallo F, et al. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93(5)1534–1539
   PubMed Web of Science ®Google Scholar
• Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, et al. Chemotherapy – induced mobilisation of karyotypically normal PBSC for autografing in CML. Bone Marrow Transplant 1998; 21: 1029–1036
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85: 3257–3263
   PubMed Web of Science ®Google Scholar
• Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Gahrton G, et al. Danish-Swedish CML Intensive treatment in order to minimize the Ph-positive clone in CML Bone Marrow Transplant 1996; 17((Suppl 3))S63–S64
   Google Scholar
• Frassoni F, Podesta M, Piaggio G, Rosti V, Pitto A, Benvenuto F, et al. Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. Br J Haematol 1999; 104(3)538–545
   PubMed Web of Science ®Google Scholar
• Chalmers E A, Franklin I M, Kelsey S M, Newland A C, Clark R E, Sproul A M, et al. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilisarion of Philadelphia -negative peripheral blood stem cells. Br J Haematol 1997; 96: 627–634
   PubMed Web of Science ®Google Scholar
• Carella A M, Frassoni F. ICE, mini ICE or high-dose hydroxyurea to mobilise Philadelphia negative PBPC in chronic myelogenous leukaemia. Br J Haematol 1996; 95: 213–215
   PubMed Web of Science ®Google Scholar
• Pratt G, Johnson R J, Rawstron A C, Barnard D L, Morgan G J, Smith G M. Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF. Bone Marrow Transplant 1998; 21: 455–460
   PubMed Web of Science ®Google Scholar
• Carella A M, Beltrami G, Corsetti M T. Autografting in chronic myeloid leukemia. Semin Hematol 2003; 40(1)72–78
   PubMed Web of Science ®Google Scholar
• Khouri I F, Kantarjian H M, Talpaz M, Giralt S, Rios M O, Hester J P, et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: MD Anderson experience. Bone Marrow Transplant 1996; 17: 775–779
   PubMed Web of Science ®Google Scholar
• Mehta J, Mijovic A, Powles R, Pagliuca A, Singhal S, Czepulkowski B, et al. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Bone Marrow Transplant 1996; 17: 25–29
   PubMed Web of Science ®Google Scholar
• Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta Haematol 2005; 113(3)155–162
   PubMed Web of Science ®Google Scholar
• Bhatia R, Verfaille C M, Miller J S, McGlave P B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood 1997; 89: 2623–2634
   PubMed Web of Science ®Google Scholar
• Hui C H, Goh K Y, White D, Branford S, Grigg A, Seymour J F, et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003; 17(5)821–828
   PubMed Web of Science ®Google Scholar